Association Between Serum Ferritin Level and Severity of Liver Disease and Development of HCC in Cirrhotic Patients

NCT05401890 | Unknown

• 1 other identifier: Serum ferritin level
• Study Type: observational
• Target: 102
• Locations: 0 countries
• Sites: N/A

Brief Summary

Association between serum ferritin level and severity of liver disease and development of HCC in cirrhotic patients .

Conditions

HCC

Outcome Measures

Primary Outcomes (1)

• Association between serum ferritin level and severity of liver disease and development of HCC in cirrhotic patients .

  The relation between serum ferritin level and severity of liver disease and development of HCC in cirrhotic patients

  One year

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with liver cirrhosis of both sexes with and without HCC regardless of the aetiology of chronic liver disease

You may qualify if:

• Patients with liver cirrhosis of both sexes with and without HCC regardless of the aetiology of chronic liver disease

You may not qualify if:

• Patients less than 18 years Previously treated HCC patients with no evidence of recurrence or residual activity Subjects who had received blood transfusions or iron supplements during the previous 3 months.
• Other conditions associated with elevated serum ferritin e.g., malignancy other than HCC, iron overload syndromes, autoimmune disorders, chronic excess alcohol consumption and acute and chronic infections.
• Patients who will refuse to give a written consent, will be excluded from our study

Sponsors & Collaborators

• Assiut University: lead

Related Publications (1)

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2018) 68:394-424.doi: 10.3322/caac.21492 . Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, Allen C, et al.The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level. JAMA Oncol. 2017;3:1683-91.https://doi.org/10.1001/jamaoncol.2017.3055. Ibrahim AS, Khaled HM, Mikhail NN, Baraka H, Kamel H. Cancer incidence in Egypt: results of the national population-based cancer registry program. J Cancer Epidemiol. 2014;2014:437971.https://doi.org/10.1155/2014/437971 . Kabbach G, Assi HA, Bolotin G, et al. Hepatobiliary Tumors: Update on Diagnosis and Management. J Clin Transl Hepatol 2015;3:169-81. Miyanishi K, Tanaka S, Sakamoto H, Kato J. The role of iron in hepatic inflammation and hepatocellular carcinoma.Free Radic. Biol. Med.2019;133: 200-5. Wang W, Knovich MA, Coffman LG, Torti FM, Torti SV. Serum ferritin: past, present and future.Biochim. Biophys. Acta2010;1800:760-9. Wong K, Adams PC. The diversity of liver diseases among outpatient referrals for an elevated serum ferritin.Can. J. Gastroenterol.2006;20:467-70. Tran KT, Coleman HG, McCain RS, Cardwell CR. Serum biomarkers of iron status and risk of primary liver cancer: a systematic review and meta-analysis.Nutr. Cancer2019;71: 1365-73. Uchino K, Tateishi R, Fujiwara Net al. Impact of serum ferritin level on hepatocarcinogenesis in chronic hepatitis C patients.Hepatol. Res.2016;46: 259-68.

  RESULT

Central Study Contacts

Ashraf Mahmoud Osman

CONTACT

01222302327; ashrafosma@yahoo.com

Ahmed Shawkat Abdelmohsen

CONTACT

0102830699; shawkatahmed84@yahoo.com

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Doctor

Study Record Dates

• First Submitted: May 30, 2022
• First Posted: June 2, 2022
• Study Start: August 1, 2022
• Primary Completion: August 1, 2023
• Study Completion: October 1, 2023
• Last Updated: July 26, 2022

Record last verified: 2022-05